Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New

Hepatocellular carcinoma (HCC) is the most common primary liver tumour (80-90%) and represents more than 5.7% of all cancers. Although in recent years the therapeutic options for these patients have increased, clinical results are yet unsatisfactory and the prognosis remains dismal. Clinical or molecular criteria allowing a more accurate selection of patients are in fact largely lacking.

New Approaches in Locoregional Therapies for Hepatocellular Carcinoma


Hepatocellular carcinoma (HCC) represent actually the fifth most common cancer worldwide, with liver transplantation and hepatic resection who represent the standard of care of curative treatment. Unfortunately, not all patient could benefit of curative treatment. For such patients, locoregional or systemic therapies represent a valid option in order to achieve the best survival possible.

Duodéno-pancréatectomie céphalique avec résection veineuse mésentérico-portale (avec vidéo)

Radical (R0 resection) pancreaticoduodenectomy (PD) is the only treatment offering ahope of long-term survival for patients affected from pancreatic head cancer and malig-nant periampullary tumors. A fine dissection of the retroperitoneal margin close to thesuperior mesenteric artery (SMA) with en bloc retroperitoneal pancreatic tissue ablationis crucial to increase the number of R0 resection and to extend the circumferentialmargin.